KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Retained Earnings (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Retained Earnings data on record, last reported at -$26.0 million in Q3 2025.

  • For Q3 2025, Retained Earnings rose 98.79% year-over-year to -$26.0 million; the TTM value through Sep 2025 reached -$26.0 million, up 98.79%, while the annual FY2024 figure was -$2.2 billion, 25.27% down from the prior year.
  • Retained Earnings reached -$26.0 million in Q3 2025 per IONS's latest filing, up from -$28.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$24.2 million in Q1 2021 and bottomed at -$2.2 billion in Q4 2024.
  • Average Retained Earnings over 5 years is -$777.4 million, with a median of -$49.0 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: plummeted 5056.63% in 2022, then skyrocketed 98.79% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$32.7 million in 2021, then plummeted by 4276.22% to -$1.4 billion in 2022, then fell by 25.62% to -$1.8 billion in 2023, then decreased by 25.27% to -$2.2 billion in 2024, then surged by 98.85% to -$26.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$26.0 million in Q3 2025, -$28.0 million in Q2 2025, and -$28.9 million in Q1 2025.